APA (7th ed.) Citation

R, D., E, R., J, R., E, L., AM, R., M, S., . . . T, C. (2016). Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. British journal of haematology, 172(4), 628. https://doi.org/10.1111/bjh.13516

Chicago Style (17th ed.) Citation

R, Devillier, et al. "Combination Therapy with Ruxolitinib Plus Intensive Treatment Strategy Is Feasible in Patients with Blast-phase Myeloproliferative Neoplasms." British Journal of Haematology 172, no. 4 (2016): 628. https://doi.org/10.1111/bjh.13516.

MLA (9th ed.) Citation

R, Devillier, et al. "Combination Therapy with Ruxolitinib Plus Intensive Treatment Strategy Is Feasible in Patients with Blast-phase Myeloproliferative Neoplasms." British Journal of Haematology, vol. 172, no. 4, 2016, p. 628, https://doi.org/10.1111/bjh.13516.